introduction {#s1}
============

Regorafenib is an orally available, small-molecule multikinase inhibitor that blocks the activity of a variety of protein kinases involved in the regulation of tumor angiogenesis \[vascular endothelial growth factor (VEGF) receptor-1, -2, and -3 and TIE-2\], oncogenesis (KIT, RET, RAF-1, and wild-type and V600E-mutant BRAF), and the tumor microenvironment \[platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor\] \[[@MDV244C1]\]. Preclinical evidence of antitumor activity \[[@MDV244C1], [@MDV244C2]\] has been confirmed in clinical trials covering a range of advanced solid tumors, including hepatocellular carcinoma, gastrointestinal stromal tumors (GIST), and colorectal cancer \[[@MDV244C3]--[@MDV244C11]\]. Regorafenib met its primary end points (overall survival and progression-free survival, respectively) in phase III placebo-controlled trials in patients with treatment-refractory metastatic colorectal cancer \[[@MDV244C10], [@MDV244C11]\] and advanced pretreated GIST \[[@MDV244C9]\] and as a result now has international marketing authorizations for use in these settings.

Across all of these clinical trials, regorafenib showed a consistent and predictable adverse-event profile, with skin toxicities such as hand--foot skin reaction (HFSR) among the most clinically significant (see [supplementary Table S1, available at *Annals of Oncology* online](http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdv244/-/DC1)) \[[@MDV244C3]--[@MDV244C11]\]. In a meta-analysis of regorafenib trials, HFSR occurred at a rate of 61% overall and 20% at grade 3, with higher overall rates in patients with renal-cell carcinoma (71%) and GIST (60%) than in those with colorectal cancer (47%) \[[@MDV244C12]\]. HFSR is also seen with varying frequencies in patients treated with other multikinase inhibitors. A meta-analysis of clinical trials of sorafenib indicated an overall HFSR rate of 34% and a rate of grade 3 HFSR of 9% \[[@MDV244C13]\]. In a similar meta-analysis of sunitinib trials, the rates were 19% overall and 6% for grade 3 HFSR \[[@MDV244C14]\]. Although therapeutic response to other targeted agents (including sunitinib and sorafenib) has been correlated with HFSR occurrence \[[@MDV244C15]--[@MDV244C18]\], it is unknown whether this is the case for regorafenib.

The variation in incidence of HFSR across tumor types and among the different multikinase inhibitors is presumed to reflect the different molecular pathways involved and the variation in degree of target kinase inhibition between agents. It is speculated that combined inhibition of different receptors (e.g. VEGF receptor and PDGFR) may be required to trigger the dermatologic symptoms. Agents that target only one of these pathways (e.g. imatinib, which targets PDGFR, and bevacizumab, which targets VEGF) are rarely associated with HFSR \[[@MDV244C13]\], while the combination of bevacizumab and sorafenib increases the HFSR incidence over that seen with sorafenib alone \[[@MDV244C19]\]. Blockade of both pathways could alter microvascular structure or disrupt endothelial and vascular repair mechanisms, resulting in persistent damage to vessels and fibroblasts at areas of frequent trauma or friction (such as the palms of the hands, soles of the feet, and elbows) \[[@MDV244C12]\]. Vascular competence is important for tissue repair, and thus vascular damage can impair the skin\'s ability to recover from day-to-day wear and tear. In addition, regorafenib uniquely inhibits the endothelium-specific TIE-2 receptor, thus affecting angiopoietin pathways, which are responsible for vascular remodeling and are implicated in pathologic inflammation. TIE-2 inhibition may therefore also have a role in the increased risk of HFSR in regorafenib recipients \[[@MDV244C12]\].

HFSR can be troublesome for patients, affecting their ability to carry out everyday activities and get on with their lives. It is therefore important that health care professionals are able to recognize and manage the symptoms in order to reduce the impact of HFSR on patients. To this end, the aim of this review is to summarize the key pathophysiological features of regorafenib-associated HFSR and to identify and recommend appropriate approaches (including supportive interventions and treatment modifications) to manage HFSR in patients receiving regorafenib.

methods {#s2}
=======

This review has been developed as an academic collaboration between dermatologists and oncologists with expertise in the management of drug-related skin toxicities and oncologists involved in the clinical trials of regorafenib in colorectal cancer. The authors reviewed published articles identified by a literature search of the PubMed database using synonyms for regorafenib and HFSR management, as well as a general search for articles on any skin toxicities associated with anticancer therapies (including capecitabine/5-fluorouracil and kinase inhibitors). The full search strings are listed in the [supplementary Appendix, available at *Annals of Oncology* online](http://annonc.oxfordjournals.org/lookup/suppl/doi:10.1093/annonc/mdv244/-/DC1). The search, which was conducted in October 2014, was not restricted to any language, article type, or publication period, to avoid excluding potentially relevant articles. The literature review was supplemented by the authors\' own knowledge of the therapy area.

results {#s3}
=======

The regorafenib literature search identified a total of 167 articles, including primary trial reports and reviews, opinion pieces, and case studies. To date, no clinical studies of interventions to prevent or manage regorafenib-related HFSR have been published. Eight articles have provided advice on the management of regorafenib-related HFSR, in each case as part of a larger review of the management of toxicities associated with either regorafenib alone \[[@MDV244C20]--[@MDV244C25]\] or all targeted therapies in colorectal cancer \[[@MDV244C26], [@MDV244C27]\].

In general, there is little high-quality evidence from randomized clinical trials to support specific interventions for HFSR related to any kinase inhibitor, with most recommendations being based on empirical experience and expert opinion \[[@MDV244C28]--[@MDV244C39]\]. Table [1](#MDV244TB1){ref-type="table"} lists approaches that have been investigated in mostly small trials or individual cases of patients receiving other kinase inhibitors (most frequently sorafenib) \[[@MDV244C40]--[@MDV244C52]\]. Most of these HFSR management options involve topical interventions, such as corticosteroids, keratolytics, moisturizers, or phototherapy. Table 1.Management approaches for hand--foot skin reaction (HFSR) associated with licensed kinase inhibitorsReferenceKinase inhibitorInterventionOutcomeClinical studies\[[@MDV244C40]\]Sorafenib10% urea-based cream three times daily + best supportive care (*n* = 439) or best supportive care alone excluding all creams (*n* = 432), starting on day 1 of sorafenib treatment, for up to 12 weeksCompared with best supportive care alone, addition of urea-based cream resulted in: Significantly lower incidence of any-grade HFSR (*P* \< 0.001) and grade ≥2 HFSR (*P* = 0.004) at week 12Significantly longer median time to first occurrence of HFSR (*P* \< 0.001)Improved patient quality of life\[[@MDV244C41]\]SorafenibHydrocolloid dressing containing ceramide (group A, *n* = 17) versus 10% urea cream (group B, *n* = 16) for grade 1 HFSR on the soles of the feetHFSR worsened to grade 2 or 3 in 29% of patients in group A and 69% of patients in group B (*P* = 0.03)Median time to grade 2 or 3 HFSR was significantly longer in group A than in group B (*P* = 0.03)\[[@MDV244C42]\]Sunitinib, sorafenib, or axitinibTopical heparin-containing ointment, shock absorbers, and skin moisturizers (*n* = 26)HFSR grade 1 resolved completely in 8/12 patientsHFSR grade 2 symptoms reduced in 10/12 patientsHFSR grade 3 downgraded to grade 2 in 2/2 patientsFour patients required dose reductions; no patients had treatment interruption\[[@MDV244C43]\]SorafenibVitamin E 300 mg/day (*n* = 10)Marked effect after 10--12 days of initiationNo need for sorafenib dose modification\[[@MDV244C44]\]Sorafenib or gefitinibTaohongsiwu (traditional Chinese medicine; *n* = 60) versus oral vitamin B6 (*n* = 32)Significant improvements in pain relief and activities of daily living with taohongsiwu versus vitamin B6Case reports\[[@MDV244C45]\]SorafenibTopical clobetasol, cetirizine tablets, cold spongingPatient able to continue on sorafenib therapy at reduced dose\[[@MDV244C46]\]BRAF inhibitors (vemurafenib or dabrafenib)Topical steroids and keratolyticsSuccessful control of symptoms\[[@MDV244C47]\]SorafenibNarrow-band ultraviolet B phototherapyUsed to treat psoriasis but found to successfully alleviate HFSR as wellPatient had first received topical urea/emollient therapy, which had been unsuccessful\[[@MDV244C48]\]Sunitinib or imatinibTopical psoralen + ultraviolet A therapy (±methoxsalen or prednisone)Prolonged remission of symptoms while patient remained on full-dose chemotherapy\[[@MDV244C49]\]SorafenibTopical corticosteroids, podiatric management, and thermal water gelSymptom resolution with sorafenib interruption and restart at a lower dose\[[@MDV244C50]\]SorafenibTopical clobetasol propionate ointmentSymptom resolution without interruption of sorafenib therapy\[[@MDV244C51]\]SorafenibTopical prednicarbate ointment, fusidic acid cream and moisturizer (dexpanthenol)Successful control of symptoms, allowing continuation of sorafenib treatment\[[@MDV244C52]\]DabrafenibPregabalinPatient able to stop narcotics and return to normal activities within 1 week

discussion {#s4}
==========

In the absence of high-quality evidence from randomized clinical trials or detailed advice on regorafenib-specific HFSR management, the following discussion offers recommendations from the authors\' extensive clinical experience, supplemented by evidence on the management of HFSR associated with other small-molecule kinase inhibitors and chemotherapy.

regorafenib-related HFSR pathophysiology {#s4a}
----------------------------------------

Symptoms affecting the hands and feet following initiation of different systemic anticancer treatments have been reported under a variety of names, including HFSR, hand--foot syndrome, palmar--plantar erythrodysesthesia, acral erythema, toxic erythema of chemotherapy, and Burgdorf reaction \[[@MDV244C36]\]. The first report, in 1974, was in relation to mitotane therapy for hypernephroma \[[@MDV244C53]\]. Since then, variations of the syndrome (or, more probably, syndromes) have been described in association with many cytotoxic and targeted agents, especially 5-fluorouracil and capecitabine, doxorubicin and pegylated liposomal doxorubicin, docetaxel, cytarabine, sorafenib, sunitinib, and vemurafenib \[[@MDV244C34], [@MDV244C36], [@MDV244C54]\].

The features of HFSR seen with regorafenib are akin to those reported for other targeted agents and differ in important aspects (which may have implications for management) from the syndrome that clinicians may be familiar with in association with traditional cytotoxic therapies such as capecitabine (Table [2](#MDV244TB2){ref-type="table"}) \[[@MDV244C55]\]. For clarity, the terminology referring to the two forms is commonly distinguished, with HFSR referring specifically to symptoms related to targeted therapy and hand--foot syndrome being reserved for symptoms related to traditional chemotherapy; this distinction is used in the present review. In HFSR, following a prodromal phase of dysesthesia (described as a sensation developing from tingling to burning over a few days), patients develop bilateral, painful, sharply demarcated, asymmetric erythema and large, tense blisters evolving into callus-like hyperkeratosis. Pain may be out of proportion to the clinical appearance of the lesions. Symptoms typically occur at pressure-bearing points such as the palms of the hands, soles of the feet (especially the heels and metatarsal head area), elbows, and amputation sites, while they are unlikely to be seen on the dorsal hand or foot; they may also develop at other areas of friction, such as the finger tips (e.g. from frequent use of mobile devices), sides of the feet, and spaces between fingers and toes \[[@MDV244C34], [@MDV244C36], [@MDV244C49], [@MDV244C56], [@MDV244C57]\]. The symptoms are typically more localized, and edema is less likely, in patients receiving multikinase inhibitors than in those receiving cytotoxic agents \[[@MDV244C26], [@MDV244C58]\]. With traditional cytotoxic agents, the hands are likely to be affected more than the feet, while, for multikinase inhibitors, the feet may be more likely to be affected \[[@MDV244C36]\]. Table 2.Differing features of hand--foot syndrome and hand--foot skin reaction (created based on author knowledge and using \[[@MDV244C55]\])Hand--foot syndromeHand--foot skin reactionAssociated with traditional cytotoxic chemotherapies, including cytarabine, anthracyclines, fluoropyrimidines, and taxanesAssociated with multikinase inhibitors (e.g. sorafenib, sunitinib, and regorafenib) and BRAF inhibitors (e.g. vemurafenib and dabrafenib)Onset weeks to months after starting treatmentOnset days to weeks after starting treatmentMechanism unclear, but doxorubicin-induced symptoms may be caused by concentration of cytostatic in skin via eccrine sweat ductsWith multikinase inhibitors, mechanism may be insufficient repair to frictional trauma due to inhibition of PDGFR and VEGFR\
With BRAF inhibitors, mechanism may be paradoxical hyperproliferationCharacterized by: DysesthesiaErythemaScalingCharacterized by: DysesthesiaErythemaPainBlisters and hyperkeratosis (with surrounding erythema) at pressure pointsSymmetrical, diffuse distributionLocalized at pressure points[^1]

The difference in appearance of HFSR due to targeted therapies compared with the hand--foot syndrome seen in patients receiving cytotoxic chemotherapy may reflect different underlying pathological processes. For example, there is evidence to show that doxorubicin-associated hand--foot syndrome may be a direct toxic effect resulting from transport of the active agent to the skin surface via sweat \[[@MDV244C59]--[@MDV244C61]\], whereas no such effect has been found in patients receiving sorafenib \[[@MDV244C62]\] and evidence is inconclusive for sunitinib \[[@MDV244C63], [@MDV244C64]\]. In contrast, as described earlier, multikinase inhibitors may play a role in disrupting the natural balance of vascular and epidermal trauma and repair at sites of pressure and friction through effects on a variety of molecular signaling pathways \[[@MDV244C19], [@MDV244C65]\].

Time-to-event analyses in phase III trials of regorafenib confirmed clinical experience that, as with sorafenib and sunitinib \[[@MDV244C66]\], HFSR tends to occur shortly after the start of treatment (median time to first occurrence was 15 days in the phase III study in colorectal cancer \[[@MDV244C67]\]), and the severity is also likely to peak early (medium time to maximum severity was 22 days in that study \[[@MDV244C67]\]). In contrast, the occurrence of capecitabine-induced hand--foot syndrome is typically more delayed (median time to first presentation was 72--79 days \[[@MDV244C68], [@MDV244C69]\]).

With appropriate intervention, including prespecified dose reductions described in this review, patients in the regorafenib clinical trials were largely able to continue treatment, with few patients (0%--1.4%) stopping treatment permanently because of HFSR. In clinical practice, however, with a wider range of patients than are eligible to take part in clinical trials, the rate of permanent discontinuation due to HFSR is often higher, emphasizing the need for optimal recognition, prevention, and management of this clinically significant syndrome.

impact of HFSR {#s4b}
--------------

While HFSR is not considered to be a life-threatening event (although the potential risk of superinfection of the damaged skin should not be ignored \[[@MDV244C55]\]), the location of the lesions can have a substantial impact on patients by preventing them from walking or carrying out daily tasks. No studies have yet directly assessed the impact of regorafenib-related HFSR on patients\' quality of life. However, cutaneous toxicities in general and HFSR in particular have been shown to decrease quality of life and impair social functioning in patients receiving other targeted therapies, such as sorafenib and sunitinib \[[@MDV244C70]--[@MDV244C73]\]. In some cases, particularly if the patient does not report symptoms early enough or there is no appropriate and effective management plan in place, there is a risk that the HFSR may be so severe that the patient is unable or unwilling to continue anticancer therapy. In contrast, it has been shown that appropriate and effective intervention to manage cutaneous toxicities can improve quality of life \[[@MDV244C44], [@MDV244C74], [@MDV244C75]\].

No data on the economic cost of treating regorafenib-related HFSR have been reported. However, an analysis of the cost of managing cutaneous toxicities associated with sorafenib and sunitinib for cancer at a single US dermatology department found that sorafenib-related HFSR was the most costly cutaneous toxicity to manage, accounting for a median medication cost of \$968 per patient \[[@MDV244C76]\]. While this US cost analysis cannot be directly extrapolated to European health care systems, it seems likely that appropriate, timely, and effective intervention to pre-empt and manage regorafenib-related HFSR would reduce the burden of symptoms on patients and limit the cost of managing those symptoms by preventing them from becoming chronic and severe.

prevention and management of regorafenib-related HFSR {#s4c}
-----------------------------------------------------

The goals of HFSR management are to reduce the risk of HFSR developing and to alleviate symptoms of established HFSR, to enable patients to maintain their quality of life and continue to receive effective anticancer therapy.

Although no study has been undertaken to identify patients most likely to be at risk of regorafenib-related HFSR, Dranitsaris et al. have developed and validated a prediction index for sorafenib-related HFSR, based on female sex, poor performance status (Eastern Cooperative Oncology Group 2 or lower), lung or liver metastases at baseline, two or more organs involved, baseline white blood cell count above 5.5 × 10^9^ cells/l, and week of therapy (up to week 8, with highest scores assigned to weeks 3--7) \[[@MDV244C77]\]. In the absence of clinical research into risk factors specifically related to regorafenib, these sorafenib-associated factors may be of assistance in prompting a heightened index of suspicion of HFSR risk in patients receiving regorafenib. It is currently unknown whether specific genetic polymorphisms may exist, as they do for sorafenib and sunitinib, that may increase a patient\'s risk of high-grade toxicity \[[@MDV244C78]\].

Before starting treatment with regorafenib, it is important to establish a baseline against which to compare any incipient symptoms. Patients should have a full-body examination by an appropriately experienced health care professional, supported if feasible by a formal assessment of quality of life (using an established tool such as the Skindex \[[@MDV244C79]\] or Dermatology Life Quality Index \[[@MDV244C80]\], or a specific HFSR tool such as the HFS-14 \[[@MDV244C81]\] once validated in patients receiving multikinase inhibitors). Clinical examination should pay special attention to the hands and feet to identify predisposing factors, such as hyperkeratosis, eczema, or fungal disease. Any identified risk factors should be treated, ideally before starting regorafenib therapy, for example with manicures or pedicures to remove hyperkeratotic skin or referral to a podiatrist or dermatologist (particularly for those with comorbidities, such as diabetes). For patients with evidence of abnormal weight bearing, mechanical support and correction should be considered. Patients should be advised to use alcohol-free moisturizers liberally and to avoid hot water (e.g. dishwashing or hot baths and showers), because heat may exacerbate symptoms. Patients should also avoid constrictive footwear and reduce friction on the skin when applying lotion, during massages, or in the process of everyday tasks, such as typing. Vigorous exercise or activities that place undue stress on the hands and feet (such as heavy lifting or long walks) should be avoided, especially during the first month, to reduce the risk of blistering. Patients should use padded insoles in their shoes throughout treatment to reduce pressure on the feet, and they should be advised to wear thick cotton gloves or socks to prevent injury and keep palms and soles dry \[[@MDV244C32], [@MDV244C34], [@MDV244C37], [@MDV244C39]\].

Once they start treatment, patients should be monitored frequently for signs of incipient HFSR, for example during the first week of treatment and then every 1--2 weeks during the first two cycles and every 4--6 weeks thereafter \[[@MDV244C20], [@MDV244C23], [@MDV244C25]\]. This surveillance schedule reflects the time profile of new HFSR cases reported in the phase III CORRECT study, with most cases developing in the first couple of cycles \[[@MDV244C67]\]. This pattern is also seen in clinical practice and has prompted some clinicians to explore the use of a reduced starting dose, with the potential to escalate to the full 160 mg dose if patients are able to tolerate treatment \[[@MDV244C82], [@MDV244C83]\]. To date, however, such experience is restricted to single centers and small case series, and a reduced starting dose of regorafenib has not been evaluated in a controlled clinical trial.

If symptoms do develop, the patient should be managed by a multidisciplinary team \[[@MDV244C32], [@MDV244C37]\] including oncologist, dermatologist, podiatrist, primary-care physician, and nurse. It is important to attempt to identify the cause of the symptoms, ruling out alternative causes, such as erythema multiforme, fungal infections, other types of drug reactions, or persisting sensory neuropathy following cytotoxic chemotherapy.

The management approach depends on the severity of the symptoms, graded using the National Cancer Institute\'s Common Terminology Criteria for Adverse Events version 4 \[[@MDV244C84]\] (Figure [1](#MDV244F1){ref-type="fig"}). Options include physical protection of the affected area and symptomatic interventions (Table [3](#MDV244TB3){ref-type="table"}), as well as consideration of regorafenib treatment modifications (Table [4](#MDV244TB4){ref-type="table"}). Table 3.Recommended supportive measures to prevent or manage hand--foot skin reactionPurposeInterventionTimingControl of callusesCheck condition of hands and feet\
Suggest a manicure/pedicure to remove hyperkeratotic skin\
Recommend pumice stone use for callus or 'rough spot' removalBefore initiating treatment with regorafenibAvoid pressure points\
Avoid items that rub, pinch, or create frictionDuring regorafenib treatmentMoisturizersNonurea-based creams or ointmentsApply liberally when needed, especially after hand washingKeratolytic creams10%--40% urea-based\
5%--10% salicylic acidUse sparingly and only to affected (hyperkeratotic) areasPain controlTopical analgesics, e.g. lidocaine 2%--4%As neededManagement of grade 2--3 symptomsTopical corticosteroids, e.g. clobetasol 0.05%\
Avoid systemic steroidsTwice dailyCushioning/protection of tender areasUse socks/gloves to cover moisturized areas\
Wear well-padded footwear\
Use insole cushions or inserts (e.g. silicon, gel)\
Foot soaks with tepid water and Epsom saltsAs needed Table 4.Regorafenib dose modifications to manage hand--foot skin reaction as outlined in the phase III clinical trial protocols \[[@MDV244C9]--[@MDV244C11]\]Hand--foot skin reaction gradeOccurrenceSuggested dose modification^a^Grade 1: numbness, dysesthesia, paresthesia, tingling, painless swelling, erythema, or discomfort of the hands or feet that does not disrupt the patient\'s normal activitiesAnyMaintain dose level and institute immediate supportive measures for symptomatic reliefGrade 2: painful erythema and swelling of the hands or feet and/or discomfort that affects the patient\'s normal activitiesFirst occurrenceConsider decreasing dose by one dose level and institute immediate supportive measures. If no improvement, interrupt therapy for a minimum of 7 days, until toxicity resolves to grade 0--1^b^No improvement within 7 days or second occurrenceInterrupt therapy until toxicity resolves to grade 0--1. When resuming treatment, treat at reduced dose level^b^Third occurrenceInterrupt therapy until toxicity resolves to grade 0--1. When resuming treatment, decrease dose by one additional dose level^b,c^Fourth occurrenceDiscontinue therapyGrade 3: moist desquamation, ulceration, blistering, or severe pain of the hands or feet, or severe discomfort that causes the patient to be unable to work or perform activities of daily livingFirst occurrenceInstitute immediate supportive measures. Interrupt therapy for a minimum of 7 days until toxicity resolves to grade 0--1. When resuming treatment, decrease dose by one dose level^b^Second occurrenceInstitute immediate supportive measures. Interrupt therapy for a minimum of 7 days until toxicity resolves to grade 0--1. When resuming treatment, decrease dose by one additional dose level^b,c^Third occurrenceDiscontinue treatment permanently[^2][^3][^4] Figure 1.Palmar--plantar erythrodysesthesia syndrome, grades 1--3, according to the National Cancer Institute Common Terminology Criteria for Adverse events, version 4 \[[@MDV244C84]\]. Grade 1: numbness, dysesthesia, paresthesia, tingling, painless swelling, erythema, or discomfort of the hands or feet that does not disrupt the patient\'s normal activities. Grade 2: painful erythema and swelling of the hands or feet and/or discomfort that affects the patient\'s instrumental activities of daily living. Grade 3: moist desquamation, ulceration, blistering, or severe pain of the hands or feet, or severe discomfort that causes the patient to be unable to work or perform self-care activities of daily living. Note that, as discussed in the text, hand--foot skin reaction due to small-molecule kinase inhibitors may have a different manifestation, so the descriptions here may not match symptoms experienced by patients receiving regorafenib. Photos provided by Siegfried Segaert and Eric Van Cutsem.

Grade 1 HFSR is characterized by minimal skin changes or dermatitis (e.g. erythema, edema, or hyperkeratosis) without pain \[[@MDV244C84]\]. Health care professionals should reinforce patient education about preventing symptoms and institute supportive measures such as control of hyperkeratotic areas and moisturizers. Patients should be advised to avoid hot water and to use emollients and creams frequently to maintain moisture and prevent loss of dermal integrity. If disease is present at an unexpected site, unusual sources of friction in the area should be identified, such as shoelaces rubbing on the anterior ankle. Keratolytics, such as 10%--40% urea or 5%--10% salicylic acid, may be indicated for hyperkeratotic lesions, while topical analgesics (e.g. lidocaine gel) can help to relieve pain. Oozing lesions may be treated with baths containing an antiseptic, such as potassium permanganate, chlorhexidine gluconate, or diluted bleach. Patients should be advised to wear cotton gloves and socks, including at night, to prevent further injury, to help retain moisture, and to increase penetration of topical medications. The dose of regorafenib does not need to be modified at this level of toxicity (see Table [4](#MDV244TB4){ref-type="table"}). A 2-week follow-up in the clinic is recommended, when special attention should be paid to the palms of the hands and soles of the feet. Patients with unique skin symptoms or whose HFSR persists despite the above recommendations should be referred to a dermatologist \[[@MDV244C37], [@MDV244C39]\].

Grade 2 HFSR manifests with painful skin changes (e.g. peeling, blisters, bleeding, edema, or hyperkeratosis) and limits instrumental activities of daily living \[[@MDV244C84]\]. The goal of management is to control hyperkeratosis, cushion callused areas, moisturize skin, and relieve discomfort. Treatment should be as for grade 1 toxicity (including creams containing urea or salicylic acid for hyperkeratotic areas and topical analgesics for pain), with the addition of clobetasol 0.05% ointment or foam twice daily for erythematous areas. Patients should be assessed for bleeding risk and kidney function before systemic pain medications (e.g. nonsteroidal anti-inflammatory drugs, opioids, or GABA agonists such as gabapentin or pregabalin) are used \[[@MDV244C37], [@MDV244C39]\]. If necessary, the regorafenib dose can be reduced by one level for a minimum of 7 days (maximum 28 days), until the HFSR reaches grade 1 or 0, at which point patients can resume treatment at the full starting dose. If symptoms recur on re-exposure to regorafenib, treatment interruption for at least a further 7 days can be considered, with the drug reintroduced at a reduced dose thereafter (see Table [4](#MDV244TB4){ref-type="table"} for full recommendations on regorafenib treatment modifications).

Grade 3 HFSR is the most severe grade, involving painful skin changes (e.g. peeling, blisters, bleeding, edema, or hyperkeratosis) limiting self-care activities of daily living \[[@MDV244C84]\]. The goal of management is to reduce symptoms and prevent further negative impact on the patients\' quality of life. Patients should have symptomatic treatment as indicated for grades 1 and 2, with regorafenib treatment interrupted for a minimum of 7 days (maximum 28 days) until the HFSR reaches grade 1 or 0; regorafenib should then be resumed at one dose level lower than the previous dose (see Table [4](#MDV244TB4){ref-type="table"}). If toxicity does not recur, it may be possible to re-escalate back to the full starting daily dose. However, if HFSR recurs on re-exposure to regorafenib, treatment may need to be interrupted again for at least a further 7 days and reintroduced at a further reduced dose (minimum 80 mg/day) or discontinued permanently if supportive measures and treatment modifications do not control symptoms (see Table [4](#MDV244TB4){ref-type="table"}). Additional supportive measures include topical corticosteroids and topical antibiotics. Following control of an acute episode of erythema (with or without blisters), patients may develop hyperkeratotic, tender lesions. In these cases, topical keratolytic creams can be used, for example containing 10%--40% urea or 5%--10% salicylic acid. In addition, antiproliferative agents such as tazarotene 0.1% may be of benefit \[[@MDV244C37], [@MDV244C39]\].

patient education {#s4d}
-----------------

As regorafenib is an oral agent, patients will usually take each dose in their home, rather than under direct supervision of a health care professional. It is therefore critical that patients are educated on the risk of HFSR and can identify the symptoms early, so that they can take appropriate steps to reduce the impact on their daily lives. Nurses play a key role in ensuring that patients understand the information that they are given; a checklist published by De Wit et al. can help to ensure that the patient is given consistent and comprehensive advice \[[@MDV244C23]\]. Verbal communications should be supported by written materials that patients can refer to at later times---an illustrated pamphlet on the early signs and symptoms of HFSR can encourage patients to be proactive about pre-empting, detecting, and managing HFSR.

Patients should be reassured that HFSR is not a reason for discontinuing regorafenib if it is managed early and proactively. The health care team should take care to explain the rationale for treatment modifications (i.e. that there is a need to find a balance between tolerability and the most effective dose). Frequent communication between patients and health care professionals is encouraged; clinical assessment (whether face to face or by telephone) during the first week of treatment and at regular intervals thereafter (e.g. every 1--2 weeks during the first two cycles) ensures that symptoms are detected at the earliest possible stage \[[@MDV244C20], [@MDV244C23]\]. Such frequent contact has an important role in reinforcing patient education about HFSR prevention and management \[[@MDV244C39]\].

conclusions {#s5}
===========

The multikinase inhibitor regorafenib has proven efficacy in terms of prolonging overall and progression-free survival and is indicated for use in patients with advanced colorectal cancer or GIST. Evidence from clinical trials and real-world experience indicates that there is a high risk that patients will experience HFSR. However, this potentially troublesome adverse event need not prevent patients from receiving effective anticancer treatment with regorafenib, as long as health care professionals and patients understand the risk, take appropriate preventive actions, recognize early symptoms, and institute supportive measures and appropriate dose adjustments as outlined in this review and summarized in Figure [2](#MDV244F2){ref-type="fig"}. The recommendations are based on tried-and-tested empirical experience and the expert opinions of the authors, in the absence of randomized clinical trials of specific symptomatic treatments. Future clinical trials are needed that are designed to formally assess interventions to manage HFSR and other skin toxicities related to multikinase inhibitors such as regorafenib. Figure 2.Regorafenib-related hand--foot skin reaction management approaches.
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[^1]: PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endothelial growth factor receptor.

[^2]: ^a^Dose level 0 (standard dose) = 160 mg orally once daily (4 × 40 mg tablets of regorafenib); dose level −1 = 120 mg orally once daily (3 × 40 mg tablets); dose level −2 = 80 mg orally once daily (2 × 40 mg tablets). A more conservative dose modification approach, if medically indicated, is acceptable.

[^3]: ^b^If toxicity returns to grade 0--1 after dose reduction, dose re-escalation is permitted at the discretion of the investigator.

[^4]: ^c^Patients requiring more than two dose reductions (i.e. to \<80 mg) should go off protocol therapy.
